Celldex Therapeutics Q4 EPS $(0.83) Misses $(0.74) Estimate, Sales $4.13M Beat $840.00K Estimate
Portfolio Pulse from Benzinga Newsdesk
Celldex Therapeutics (NASDAQ:CLDX) reported Q4 earnings with a per-share loss of $(0.83), missing the $(0.74) estimate, and sales of $4.13M, surpassing the $840.00K estimate. This represents a 48.21% increase in losses and a 156.04% increase in sales compared to the same period last year.
February 26, 2024 | 12:06 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Celldex Therapeutics reported a larger-than-expected Q4 loss per share but significantly exceeded sales estimates, indicating mixed financial health.
The larger-than-expected loss per share could negatively impact investor sentiment in the short term, suggesting potential downward pressure on the stock price. However, the significant beat on sales estimates indicates strong revenue growth, which could counterbalance the negative impact of the earnings miss. The mixed nature of these results makes the short-term impact on the stock price uncertain, hence a neutral score.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100